Most protocols run 4 weeks, with reassessment at the 4-week mark to evaluate symptom response and adjust future dosing if needed
However, it is important to note that more research is necessary, and NAD therapy should be integrated into a broader treatment plan under medical supervision
This page covers Glow Stack dosing, timing, and supply planning
That narrowed focus supports stronger quality control, from sourcing and synthesis all the way through lyophilization and packaging
Some websites describe it as a remarkable peptide with almost no discussion of potential risks
More serious risks to be aware of include: Pancreatitis: As with other GLP-1 receptor agonists, there is a theoretical and observed risk of acute pancreatitis